Clinical Study
Influence of IL10 (G1082A) and TNFα (G308A) Polymorphisms on the Survival of Pediatric Patients with ALL
Table 2
Patient characteristics according tothe monitoring statusin ALL (
).
| | | TNFα AA (%) | TNFα A (%) | TNFα GG (%) | IL10 AA (%) | IL10 AG (%) | IL10 GG (%) | |
| | Followup | | | | | | | | | <37 months | 5 (4.7) | 31 (29.5) | 16 (15.3) | 15 (14.3) | 27 (25.7) | 10 (9.5) | 0.0358 ‡ | | ≥37 months | 7 (6.7) | 30 (28.5) | 16 (15.3) | 11 (10.5) | 24 (22.8) | 18 (17.2) | 0.4332 | | Living | 7 (6.7) | 46 (43.8) | 24 (22.9) | 13 (12.4) | 41 (39.0) | 23 (22.0) | 0.3484 | | Death | 5 (4.7) | 15 (14.3) | 8 (7.6) | 13 (12.4) | 10 (9.5) | 5 (4.7) | 0.0725 | | Ratio (D/L) | 0.71 | 0.32 | 0.33 | 1.0 | 0.24 | 0.21 | |
|
|
value by test, ‡ value significant, L: living, and D: death.
|
